Business Context and Reporting Period
Company: Curis, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2003
Business Overview: Curis is a therapeutic drug development company focused on modulating regulatory signaling pathways (specifically Hedgehog and Bone Morphogenetic Protein pathways) to repair and regenerate human tissues. The company has no manufacturing or sales infrastructure and relies on strategic collaborations with pharmaceutical partners (Ortho Biotech, Genentech, Wyeth) to fund development and commercialize products. Key therapeutic areas include kidney disease, cancer, neurological disorders, and hair growth regulation.
Key Financial Metrics
| Metric (in thousands) | 2003 | 2002 |
|---|---|---|
| Total Revenues | $11,048 | $18,391 |
| Net Loss | $(11,623) | $(82,315) |
| Net Loss Applicable to Common Stockholders | $(11,894) | $(83,038) |
| Research & Development Expenses | $13,399 | $14,058 |
| General & Administrative Expenses | $5,855 | $8,160 |
| Cash, Cash Equivalents & Marketable Securities | $35,148 | $36,573 |
| Working Capital | $34,278 | $36,293 |
| Accumulated Deficit | $(649,068) | $(637,174) |
Note: The company has never been profitable and does not expect to achieve profitability in the foreseeable future.
Material Changes vs. Prior Period
- Revenue Decline: Total revenues decreased by approximately 40% from $18.4 million in 2002 to $11.0 million in 2003. This was primarily due to the absence of the $14 million one-time payment received from Stryker in 2002 for the buy-out of royalty obligations on OP-1.
- Significant Loss Reduction: Net loss improved dramatically from $82.3 million in 2002 to $11.6 million in 2003. The 2002 loss was heavily impacted by a $64.1 million non-cash goodwill impairment charge, a $5.3 million impairment of property and equipment, and $3.5 million in restructuring expenses related to a business realignment.
- Operating Expenses: General and administrative expenses decreased by 28% due to reduced personnel costs and legal fees following the 2002 realignment. R&D expenses remained relatively flat, decreasing slightly by 5%.
- Collaboration Revenue Recognition: In 2003, the company recognized $8.6 million in previously deferred revenue upon the termination of its collaboration with Micromet AG. Conversely, revenue from the ES Cell International collaboration ceased in late 2003.
Guidance, Outlook, and Risks
- Liquidity Outlook: Management believes existing capital resources (cash and marketable securities of ~$35 million) are sufficient to fund operations into the first half of 2006.
- Strategic Partnerships:
- Genentech: A June 2003 agreement for Hedgehog pathway inhibitors in cancer therapy includes a $5 million upfront fee and $4 million in maintenance fees.
- Wyeth: A January 2004 agreement (subsequent to year-end) for Hedgehog agonists in neurological disorders includes a $1.5 million license fee and stock purchase.
- Ortho Biotech: Continues to fund the development of BMP-7 for kidney disease.
- Risks and Contingencies:
- Financing Needs: The company will require substantial additional funding to continue R&D. Failure to secure financing could materially adversely affect operations.
- Development Uncertainty: All product candidates are in preclinical stages (except PYY peptide with Amylin, which has an IND filed). Success is highly uncertain.
- Impairment Charges: In Q4 2003, the company recorded a $1.7 million impairment charge for a note receivable from Micromet AG due to Micromet's financial difficulties.
- Stock Volatility: The company notes significant volatility in its stock price and the risk of delisting from NASDAQ if listing requirements are not met.
Investor Verification Checklist
- Cash Runway: Verify the accuracy of the "first half of 2006" liquidity projection given the high burn rate and lack of product revenue.
- Deferred Revenue: Review the $8.3 million in deferred revenue related to the Genentech collaboration and the assumptions regarding the recognition timeline (straight-line through 2010).
- Collaboration Dependencies: Assess the risk that key partners (Genentech, Ortho Biotech, Wyeth) may alter development priorities or terminate agreements, which would eliminate future milestone and royalty revenue.
- Impairment History: Note the history of significant non-cash impairment charges (goodwill, assets, receivables) which may indicate underlying valuation risks.
- Patent Portfolio: Confirm the status of the 164 issued and 121 pending patents, as the business model relies entirely on intellectual property licensing.